Prolonged Remission Induced by Phenofibrate in Children Newly Diagnosed With Type 1 Diabetes.
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate of the effect of phenofibrate on the functions
of beta cells in children with new diagnosis of type 1 diabetes. The main question it aims to
answer is: whether phenofibrate may prolong residual beta-cell function therefore own insulin
secretion. Participants will be asked to take a phenofibrate or identically appearing placebo
(a neutral substance), orally, once daily, for 12 months with no knowledge what is
administred to them. They will be invited for follow-up visits including blood tests every 3
months. Researchers will be monitoring the two groups for the safety of the phenofibrate, and
at the trial end they compare the residual insulin secretion results in two groups.